Evaluation of plasma EGFR mutation as an early predictor of response of erlotinib plus bevacizumab treatment in the NEJ026 study

BACKGROUND: The NEJ026 Phase 3 study demonstrated that erlotinib and bevacizumab (BE)-treated NSCLC patients with EGFR mutations had significantly better progression-free survival (PFS) than those treated with erlotinib alone (E). This study included a prospective analysis of the relationship betwee...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:EBioMedicine
Main Authors: Fukuhara, Tatsuro, Saito, Haruhiro, Furuya, Naoki, Watanabe, Kana, Sugawara, Shunichi, Iwasawa, Shunichiro, Tsunezuka, Yoshio, Yamaguchi, Ou, Okada, Prof Morihito, Yoshimori, Kozo, Nakachi, Ichiro, Gemma, Prof Akihiko, Azuma, Koichi, Kurimoto, Futoshi, Tsubata, Yukari, Fujita, Yuka, Nagashima, Hiromi, Asai, Gyo, Watanabe, Satoshi, Miyazaki, Masaki, Hagiwara, Prof Koichi, Nukiwa, Prof Toshihiro, Morita, Prof Satoshi, Kobayashi, Prof Kunihiko, Maemondo, Prof Makoto
Formato: Artigo
Idioma:Inglês
Publicado em: Elsevier 2020
Assuntos:
Research paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7334809/
https://ncbi.nlm.nih.gov/pubmed/32629391
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ebiom.2020.102861
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados